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Quercus infectoria, sejenis ramuan perubatan yang sangat ampuh telah 
digunakan secara meluas dalam budaya orang melayu bagi pelbagai kegunaan. Kajian 
terdahulu telah membuktikan aktiviti antimalaria oleh Q.infectoria, namun secara 
tepatnya, unsur fitokimia yang menyebabkan aktiviti antimalaria dalam tumbuhan ini 
masih belum ditemui walaupun bertahun-tahun usaha penyelidikan telah giat 
dilakukan. Laporan telah mendapati bahawa pyrogallol telah dijumpai pada 
Q.infectoria. Pyrogallol, sejenis sebatian organik, mempunyai keupayaan untuk 
menghasilkan radikal bebas sebagaimana ubat antimalaria lain seperti artemisinin. Ini 
menjadikan artemisinin sebagai ubat yang boleh digunakan sebagai mekanisme untuk 
meramalkan tindakan pyrogallol terhadap P.falciparum di dalam kajian ini.  Laporan 
telah menunjukkan bahawa “reactive oxygen species” (ROS) yang dihasilkan oleh 
artemisinin dalam vakuol pencernaan parasit melalui pengaktifan “endoperoxide 
bridge” mungkin mengakibatkan kematian parasit. Kajian lain telah melaporkan 
bahawa artemisinin memperlihatkan pencegahan secara langsung terhadap H--ATPase 
jenis-V, pam proton yang terletak di dalam membran vakuol pencernaan di mana 
ketidakaktifan boleh menyebabkan perubahan pH pada organel ini. Oleh itu, ujian 
berdasarkan aliran sitometri telah dilakukan untuk mengukur pH vakuol pencernaan 
selepas rawatan dengan pyrogallol dan artemisinin. Ujian malaria SYBR Green 1 
(MSF) berasaskan pendarfluor telah digunakan untuk menentukan aktiviti antimalaria 
oleh pyrogallol terhadap chloroquine-sensitive strain (3D7) pada P. falciparum 
xxi 
 
dengan menentukan 50% pencegahan kepekatan (IC50). Keluk penentukuran pH telah 
dibina dengan menggunakan fluorescein isothiocyanate (FITC) -dextran, penunjuk 
ratiometrik pH yang telah dimasukkan ke dalam vakuol pencernaan parasit trophozoite 
tahap terpencil yang diletakkan ke dalam penyangga pelbagai nilai pH dengan 
kehadiran ionophore, carbonyl cyanide m-chlorophenylhydrazone (CCCP). Parasit 
bebas CCCP telah memperlihatkan keseimbangan pH vakuol pencernaan pada 5,42 ± 
0,11, oleh itu mengesahkan potensi penggunaan lekuk penentukuran pH yang telah 
dihasilkan. Seterusnya, kepekatan artemisinin “IC50-4 hours (60 nM) and near IC50-4 hours 
(15 and 30 nM)” telah dipilih dari kajian sebelumnya untuk memastikan perubahan 
pH vakuol pencernaan yang telah diperhatikan dalam eksperimen berikutnya bukan 
disebabkan oleh kematian parasit. Ubat uji nadi selama 4 jam dengan artemisinin (15, 
30 dan 60 nM) telah dilakukan dengan menggunakan parasit trophozoite tahap 
pertengahan untuk menentukan perubahan terhadap pH vakuol pencernaan. Kepekatan 
artemisinin yang telah dipilih telah meningkatkan pH vakuol pencernaan sebanyak 1 
(15 nM, pH = 6,6 ± 0,1), 1,48 (30 nM, pH = 7,1 ± 0,08) dan 1,6 unit pH (60 nM, pH = 
7,3 ± 0,1), masing-masing berbanding dengan vakuol pencernaan yang tidak dirawat 
(pH = 5.6 ± 0.1). Hasil yang sama dari perubahan pH vakuol pencernaan yang telah 
dicetuskan oleh satu piawai perencat pam proton, concanamycin A telah diperhatikan. 
Hasilnya menunjukkan bahawa artemisinin dapat menghalang H--ATPase jenis-V, 
menyebabkan perubahan pH pada vakuol pencernaan. Kesimpulannya, kajian ini 
menyumbang kepada pemahaman yang lebih tepat mengenai mekanisme tindakan 
pyrogallol berdasarkan hasil yang telah diperolehi dengan menggunakan artemisinin 









Quercus infectoria, a highly potent medicinal herb is widely used in a 
Malay culture in several applications. Previous studies proved the antimalarial activity 
of Q. infectoria, however the exact phytochemical constituents leading to the 
antimalarial activity of this plant remains searchable despite years of intensive research 
efforts. It has been reported that pyrogallol is found among the phytoconstituents of Q. 
infectoria. Pyrogallol, an organic compound, has a capability of generating free 
radicals like other antimalarial drugs such as artemisinin. This has made artemisinin 
an acceptable drug to predict the mechanism of action of pyrogallol against P. 
falciparum in this study. It has been reported that reactive oxygen species (ROS) 
generated by artemisinin in the parasite’s digestive vacuole through endoperoxide 
bridge activation may cause parasite death. Another study reported that artemisinin 
displays direct inhibition of V-type H+-ATPase, a proton pump located on the digestive 
vacuole’s membrane in which the inactivation might cause pH alteration of this 
organelle. Hence, the flow cytometry-based assay was performed to measure the 
digestive vacuole pH after treatment with pyrogallol and artemisinin. The malarial 
SYBR Green 1 fluorescence-based (MSF) assay was used to determine the 
antimalarial activity of pyrogallol against the chloroquine-sensitive strain (3D7) of P. 
falciparum by determining the 50% inhibitory concentration (IC50). A pH calibration 
curve was constructed by using fluorescein isothiocyanate (FITC)-dextran, a 
ratiometric pH indicator incorporated into the digestive vacuole of isolated trophozoite 
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stage parasites suspended in buffers of various pH values in the presence of an 
ionophore, carbonyl cyanide m-chlorophenylhydrazone (CCCP). The CCCP-free 
parasite displayed the steady-state digestive vacuole pH of 5.42 ± 0.11, hence 
validating the potential application of the generated pH calibration curve. 
Subsequently, the concentrations of IC50-4 hours (60 nM) and near IC50-4 hours (15 and 30 
nM) of artemisinin were selected from the previous study to ensure the pH change of 
the digestive vacuole observed in the subsequent experiment was not resulted from 
parasite death. The assay of 4-hour drug pulse with artemisinin (15, 30 and 60 nM) 
was carried out by using mid trophozoite stage parasites to determine the pH change 
of the digestive vacuole. The selected concentrations of artemisinin increased the pH 
of the digestive vacuole by 1 (15 nM, pH = 6.6 ± 0.1), 1.48 (30 nM, pH = 7.1 ± 0.08) 
and 1.6 pH unit (60 nM, pH = 7.3 ± 0.1), respectively as compared with the untreated 
digestive vacuole (pH = 5.6 ± 0.1). The same result of the pH change of the digestive 
vacuole induced by a standard proton pump inhibitor, concanamycin A was observed. 
The result indicates that artemisinin might inhibit the V-type H+-ATPase, causing the 
pH change of the digestive vacuole. In conclusion, this study contributes to a better 
understanding on the mechanism of action of pyrogallol based on the results obtained 












1.1 Background of the study 
 
Malaria is a life-threatening disease caused by Plasmodium parasites. The 
disease is often transmitted to humans via the bites of infected female Anopheles 
mosquitoes (World Health Organization, (WHO) et al., 2019). It can also be 
transmitted through blood transfusion, shared use of needles contaminated with 
infected blood, organ transplant and congenitally from a mother to her infant during 
delivery (Centres for Disease Control and Prevention (CDC), et al., 2019). Common 
symptoms and signs of malaria infection include fever and flu-like illness including 
headache, shaking chills, tiredness muscle and aches. Vomiting, diarrhoea and nausea 
may occur. The disease may result in jaundice and anaemia because of the decrease in 
erythrocyte production and increase in erythrocyte rupture. Unless immediately treated, 
the infection can be transformed to a severe form of malaria causing seizures, kidney 
failure, coma and death. 
 
The WHO estimated that there were 228 million cases of malaria 
worldwide and the number of malaria deaths was 405 000 in 2018 (WHO et al., 2019). 
In Asia, the estimated number of malaria deaths per 100 000 population was 0.7 in 
2018. Despite a significant decrease in indigenous human malaria cases in Malaysia 
in 2018 (WHO et al., 2019), 15 cases of malaria were reported by Ministry of Health 
in 2018. Furthermore, new malaria cases of several species of Plasmodium parasites 
appeared and became a serious issue (Sato et al., 2019). Generally, human malaria is
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caused by P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. Insecticide-
treated bed nets (ITNs), indoor residual spraying and antimalarial drug chemotherapies 
have a positive impact in reducing morbidity and mortality rate (WHO et al., 2019).  
 
Artemisinin is an antimalarial drug derived from a plant known as 
Artemisia annua. Artemisinin and its derivatives are a class of endoperoxide 
compounds with a desired antimalarial efficacy against chloroquine-sensitive and 
chloroquine-resistant strains of P. falciparum (Agarwal et al., 2015). The 1,2,4-
trioxane ring system, which forms the endoperoxide structural scaffold is the key 
pharmacophore and plays an important role in increasing the pharmacodynamics 
potential of endoperoxide-based antimalarial drugs (Rudrapal et al., 2016). Strategies 
have been implanted for postponing the artemisinin resistance through the use of 
artemisinin-based combination therapies (ACTs) (Yeung et al., 2004). Artemisinin 
reduces the number of parasites during the first three days of treatment, while the 
partner drug eliminates the remaining parasites. Partial resistance towards artemisinin 
and resistance towards the partner drug have however been reported in the Greater 
Mekong Subregion, which has been spread from the epicentre in Cambodia to other 
parts of Vietnam, Laos, Thailand and Myanmar (WHO et al., 2019). 
 
The antimalarial drug resistance problem sparks the screening of 
traditional medicinal plants with desired antimalarial properties (Karamati et al., 2014). 
Several traditional medicinal plants have been tested for the treatment of malaria in 
Malaysia (Karamati et al., 2014). The traditional medicinal plants that were evaluated 
for antimalarial activity against the malaria parasites include Eurycoma longifolia, 
Tinospora crispa. Azadirachta indica, Coscinium fenestratum, Quercus infectoria and 
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many more (Mohamed et al., 2015; Ahmad et al., 2016; Bedri et al., 2013; Taher et al., 
2019).  
 
Q. infectoria (Olivier) is a small tree of family Fagaceae that is mainly 
distributed in Greece and Syria (Hussein et al., 2016). The galls of this plant or called 
manjakani grow on young branches of the trees due to the attack of the gall wasps 
(Adleria gallae-tinctoria) (Basri et al., 2014.) In Malaysia, women after childbirth 
have used the galls in combination with other herbs to keep the uterine wall elastic 
(Fan et al., 2014). In other Asian countries, the galls have been used for treating 
inflammatory diseases, toothache and gingivitis (Fan et al., 2014). Q. infectoria also 
has a potency as antimalarial, antidiabetic, anticancer, antimicrobial and anti-
inflammatory (Zin et al., 2019; Magbool et al., 2018). 
 
A preliminary study has shown that the gall crude extracts of Q. infectoria 
have an in vitro antimalarial activity against a 3D7strain of P. falciparum (Zin et al., 
2019). The antimalarial effect of these gall extracts might be attributed to the abundant 
presence of phenolic compounds such as pyrogallol (Baharuddin et al., 2015; 
Venancio et al., 2016). In the present study, the efficacy of pyrogallol was assessed 
against a chloroquine-sensitive strain (3D7) of P. falciparum.  
 
Pyrogallol has a capability of generating free radicals as other antimalarial 
drug therapies (e.g. artemisinin) (Upadhyay et al., 2010; Percário et al., 2012; Torii et 
al., 1994). The free radicals generated by pyrogallol includes hydroxy radicals (OH-), 
peroxide nitrite or hydrogen peroxide H2O2 (Torii et al., 1994). This interesting finding 
leads to determination of the effect of pyrogallol on pH of the P. falciparum digestive 
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vacuole. Alteration of the digestive vacuole pH is likely to result in detrimental 
physiological disturbances of its function.  
 
1.2 Rationale of the study 
 
The P. falciparum digestive vacuole has always been the focus of the 
antimalarial drug research and development (Hayward et al., 2006). Pyrogallol are the 
phenolic compounds majorly detected in Q. infectoria. The digestive vacuole could be 
a validated target for pyrogallol by altering the pH of this organelle following 
destruction of susceptible proteins such as proton pumps located on the digestive 
vacuole’s membrane. The proton pumps such as V-type H+-ATPase and V-type H+-
translocating pyrophosphatase located at the P. falciparum digestive vacuole’s 
membrane have been known to regulate the acidic pH of this organelle (Saliba et al., 
2003). In the present study, artemisinin was utilised as alternative result to predict the 
effect of pyrogallol on the parasite’s digestive vacuole pH. Through using an 
established flow cytometry method, the change of pH of the malaria parasite’ digestive 
vacuole following treatment of artemisinin was investigated. This event might underlie 
the basis for toxicity of pyrogallol in P. falciparum and could be useful for the 









1.3 Objectives of the study 
 
1.3.1 General objective 
 
To determine changes of the digestive vacuole pH following treatments with 
pyrogallol against the malaria parasite in vitro. 
 
1.3.2 Specific objectives 
i. To determine the antimalarial activity of pyrogallol against the 
chloroquine-sensitive strain (3D7) of P. falciparum. 
ii. To measure the pH of the digestive vacuole of the chloroquine-sensitive 
strain (3D7) of P. falciparum following treatments with artemisinin, an 
alternative of pyrogallol. 
 
1.4 Experimental design 
 
The study aimed to measure the pH of the digestive vacuole of the 
chloroquine-sensitive strain (3D7) of P. falciparum treated with pyrogallol. The 
general flow for the study is illustrated in Figure 1.1. The parasites were cultured in T-
75 flasks containing washed O-positive type human blood and complete culture media 
(CCM). CCM consists of RPMI 1640 supplemented with gentamicin in H2O, 50% 
glucose in H2O, hypoxanthine in 1 M NaOH and Albumax II. Blood samples were 





The antimalarial activity of pyrogallol was performed to determine the 
concentration that kills 50% of the parasite population (IC50) by using a malarial SYBR 
Green I fluorescence-based (MSF) assay. The parasites at ring stages were 
synchronised with sorbitol to obtain a synchronous population of ring stage parasites. 
The parasites were treated for 48 hours with different concentrations of pyrogallol. 
After 48 hours, the SYBR Green I solution (2× final concentration) was added to the 
parasite suspensions and the fluorescence signal was measured (excitation and 
emission wavelengths of 490 nm and 530 nm, respectively). Giemsa-stained thin blood 
smears were also prepared at 24- and 48-hour post-treatments to observe the 
morphology of treated parasites. 
 
 The effect of artemisinin on pH of the digestive vacuole was investigated 
by using a flow cytometry-based assay. The pH of the digestive vacuole was measured 
by using FITC-dextran (a ratiometric pH indicator) incorporated into resealed 
erythrocytes by using a hypotonic dilution technique. A pH calibration curve was 
generated by incubating resealed erythrocytes in buffers (at different pH) in the 
presence of an ionophore (CCCP) to equilibrate the pH of the parasite compartments 
with the pH of the buffers. Ratios of the fluorescence intensity detected at 530 nm and 
585 nm wavelengths were plotted on a pH calibration curve. Next, synchronised 
mature stage parasites were harvested by using MACS columns and infected with 
FITC-dextran-containing resealed erythrocytes. The probe was ingested and finally 
delivered to the digestive vacuole of trophozoite stage parasites. Trophozoite stage 
parasites (36-hour post-invasion) determined by using Giemsa-stained thin blood 
smears were adjusted to 5% parasitaemia (2% haematocrit) before treatment with 
pyrogallol at different concentrations for 4 hours. The parasites were permeabilised 
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with saponin (0.035% w/v) to release FITC-dextran in the cytoplasm of resealed 
erythrocytes, allowing only FITC-dextran accumulated in the digestive vacuole to be 
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2.1 Overview of malaria 
 
Malaria is an infectious disease caused by parasites of the genus 
Plasmodium. The disease is transmitted to a healthy human by an infected female 
mosquito of the genus Anopheles. Malaria has long been considered as one of the 
leading causes of morbidity and mortality around the world (Talapko et al., 2019). 
Malaria-like symptoms have been mentioned in historical writings of ancient nations 
from different parts of the world (Newfield et al., 2017). These records mentioned 
periodical fevers and splenomegaly (Peset et al., 2015). The prevalence of malaria in 
early nations was emphasised with modern diagnostic methods that detected malaria 
antigens in Egyptian mummies dating back to 3200 B.C. (Kenawy et al., 2015). 
Recently, numerous studies have been conducted and published to solve malaria-
related issues. Various strategies have been adopted to control and eliminate the 
disease including the use of antimalarial drugs, indoor residual spraying and 
insecticide-treated bed nets (CDC, 2020a). However, malaria still remains active and 
threatens public health partly due to the drug resistance crisis especially in developing 
countries.  
 
2.2 Distribution of malaria 
 
Malaria is usually distributed in tropical and subtropical countries that are   
characterised by several climate factors such as high temperature, humidity and rainfall 
10 
 
(CDC, 2020b). Up until 2018, populations of 92 countries were possible to be infected 
with malaria and other tropical diseases (see Figure 2.1) (WHO, 2018a). In 2017, the 
number of malaria cases was 231 million cases with 416 000 fatal cases. There was a 
slight decrease in 2018 to 228 million cases with 405 000 deaths. WHO (2019) reports 
that more than half of all malaria cases were found in the WHO African Region with 
213 million cases (93%) in 2018. This is followed by the South-East Asia Region that 
had 3.4% of the cases and the Eastern Mediterranean Region with 2.1% (WHO, 2019). 
The slow decline in the number of malaria cases worldwide could be due to the drug 
resistance problem. In Malaysia, the number of malaria cases was 5 194 cases in 2010. 
It dropped to 85 cases in 2017. Finally, it is noticeable that there was a substantial 
decrease in 2018 to zero indigenous human malaria cases (Figure 2.2) (WHO, 2019). 
However, zoonotic P. knowlesi infections have been seen in number of cases in 
Malaysia, occurring mostly in Sabah and Sarawak (Hussin et al., 2020). 
 
2.3 Human malaria parasites 
 
Plasmodium species belong to the phylum Apicomplexa, which consists 
of a number of obligate intracellular parasites. Within the phylum Apicomplexa, 
Plasmodium species are grouped into the class Aconoidasida, the order Haemosporida 
and the family Plasmodiidae (Maier, 2019). There are about 156 species of 
Plasmodium that infect various species of vertebrates (CDC, 2019). Five of them can 
cause malaria infections in humans: P. malariae, P. falciparum, P. ovale, P. vivax and 
P. knowlesi (Millar et al., 2015). Out of the five human malaria parasites, P. falciparum 












Figure 2.1:     The malaria incidence rates worldwide from 2000-2017 
Most of the countries in China and the European region reported zero indigenous cases 
in 2017. Several regions including Southeast Asia were still in active malaria 
















Figure 2.2:     The malaria incidence rates from 2000-2017 in Malaysia 
Malaysian government was successful in reducing the number of malaria cases to zero 









2.4 Life cycle of the malaria parasite 
 
The malaria parasite has a complex life cycle that is involved in two 
different hosts: a human host and a female Anopheles mosquito. 
 
2.4.1 Sexual cycle of the malaria parasite within a mosquito 
 
The sexual life cycle of the malaria parasite occurs once a female mosquito 
swallows macrogametocytes (female) and microgametocytes (male) from an infected 
human during a blood meal (see Figure 2.3) (Guttery et al., 2015). Eight of 
microgametes are produced due to exflagellation of microgametocytes that each fuses 
with a macrogamete to yield a zygote in the mosquito’s midgut. The zygote becomes 
a motile ookinete throughout meiosis. Subsequently, the ookinete penetrates the 
midgut wall and becomes an oocyst. After ten days of maturation, the oocyst produces 
and releases numerous sporozoites. The sporozoites immediately migrate to the 
salivary gland and are ready to be delivered to a human host during another blood meal 
of the infected mosquito (Bennink et al., 2016; Tachibana et al., 2018). 
 
2.4.2 Asexual cycle of the malaria parasite within a human 
 
The asexual life cycle of the malaria parasite occurs once a female 
mosquito transmits sporozoites to a human during a blood feeding. The sporozoites 
enter the bloodstream and attack the liver cells to begin the exoerythrocytic cycle (see 
Figure 2.4) (Cowman et al., 2016). In the liver, the malaria parasite multiplies and 










Figure 2.3:     The sexual life cycle of the malaria parasite inside a mosquito  
Macrogametocytes (female) and microgametocytes (male) are swallowed by a female 
mosquito during a blood meal and travelled to the mosquito’s midgut. These 
gametocytes are developed into microgametes and macrogametes during maturation 
process. Zygotes are formed throughout fusion of the microgametes with the 
macrogametes and undergo meiosis to generate ookinetes. After that, the midgut wall 
is penetrated by the ookinetes that matures into oocysts and release numerous 
sporozoites when it is broken down. Then, malaria parasites are migrated to the 
















Figure 2.4: The exoerythrocytic asexual cycle of the malaria parasite within a 
human 
The exoerythrocytic stage is occurred when sporozoites enter the blood circulation 

















Figure 2.5: The intraerythrocytic asexual cycle of the malaria parasite within 
a human 
Merozoites enter the erythrocytes and mature into three distinct stages; ring stage, 







The merozoites enter the bloodstream and attack the red blood cells (RBCs) to induce 
the intraerythrocytic cycle (Martin et al., 2017). Inside the RBCs, the parasite matures 
into three stages: ring, trophozoite and schizont (Figure 2.5). Understanding the 
concept of sexual and asexual life cycles of the malaria parasite may facilitate control 
and prevent of the disease. 
 
2.5 Malaria control and prevention challenges 
 
The main objective of National Malaria Control Programs (NMCP) and 
majority of malaria activities is to decrease the morbidity and mortality rate (CDC, 
2018). Therefore, several strategies have been implemented for controlling malaria 
such as eradicating mosquitoes, developing effective vaccines and discovering new 
antimalarial drugs (Benelli et al., 2017). This has led to a tremendous decrease in 
malaria burden in the past decade. However, achieving eradication in several countries 
remains a challenge (Tizifa et al., 2018). Despite attempts for developing malaria 
vaccines, it is demonstrated to be very problematic and there is no effective malaria 
vaccine yet available on the market. (CDC, 2018). Also, attempts to control Anopheles 
mosquito populations have a limited success (Wilke et al., 2015). The limitation of 
vector control and vaccine as well as resistance of malaria parasites to antimalarial 
drugs emphasises the importance of the discovery of new antimalarial agents with new 







2.6 Treatment of malaria 
 
Antimalarial drugs are classified into several classes based on their 
chemical compounds such as antifolates (Figure 2.6A) (i.e. proguanil and 
pyrimethamine) and quinolines (i.e. plasmoquine, quinine, mefloquine, chloroquine, 
primaquine and halofantrine) (Figure 2.6B) (Golden et al., 2015; NDUNG et al., 2018). 
Other classes of antimalarial drugs include antibiotics such as tetracyclines (i.e. 
doxycycline and methacycline) (Figure 2.6C) (Corral et al., 2017) and atovaquone (i.e. 
pyronaridine) (Figure 2.6D) (Lee et al., 2018). Currently, the most used antimalarial 
drugs are endoperoxides (i.e. artesunate, dihydroartemisinin, artemether, and 
artemisinin) that target stages of the asexual life cycle of the malaria parasite (Tilley 
et al., 2016). Artemisinin-based combination therapies (ACTs) are recommended by 
WHO for the treatment of uncomplicated and complicated malaria resulted from P. 
falciparum (WHO, 2018b). 
 
2.6.1 Past antimalarial drugs 
 
Quinine, an alkaloid-type compound extracted from the cinchona bark was 
the first effective antimalarial drug used in the 1820s (Chang et al., 2016; Gachelin et 
al., 2017). From the end of the 19th century, the scientists had conducted several studies 
on synthetic antimalarial drugs to develop quinine-based compounds and obtain more 
effective alternatives for quinine (Gachelin et al., 2017). This resulted in the synthesis 
and production of plasmoquine, the first 8 aminoquinoline in 1926 (see Figure 2.6Bii) 
(Van et al,.2016). However, this drug produced unwanted toxicological side effects 
such as induction of haemolytic toxicity in patients who are glucose-6-phosphate 
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dehydrogenase (G6PD) deficient (Chu et al., 2016). Because of this issue, a new class 
of drugs, series of side-chain modified 4-aminoquinolines known as chloroquine was 
synthesised in early 1940s (Figure 2.6Biii) (Bogaczewicz et al., 2017). This drug was 
proved invaluable in the fight against malaria, highly efficacious, inexpensive and 
safer as compared to quinine due to its low toxicity (Hu et al., 2020). 
 
Chloroquine is a weak base compound, which is able to pass through the 
erythrocyte plasma membrane (EPM) and increases the digestive vacuole pH (Juge et 
al., 2015). Chloroquine becomes protonated inside the acidic digestive vacuole, 
thereby, the charged form of this drug cannot permeate the digestive vacuole’s 
membrane, leading to blockade of the drug inside this organelle (Sayeed et al., 2019). 
It is thought that chloroquine interferes with haematin biocrystallisation in the 
digestive vacuole (Ibraheem et al., 2019). The aggregation of free haematin or 
haematin-chloroquine complex could destroy the digestive vacuole’s membrane 
(Wang et al., 2017), resulting in the parasite death. However, in the late 1950s, the 
emergence of chloroquine-resistant P. falciparum strains occurred in Southeast Asia 
and in particular in Cambodia (Thu et al., 2017). 
 
As a result, numerous antimalarial drugs have been developed and used as 
alternatives for chloroquine such as atovaquone, antifolates and antibiotics. Antifolates 
are responsible for inhibiting the formation of folate cofactors that are demanded for 
nucleotide synthesis (Figure 2.6A) (Estrada et al., 2016). However, the resistance of 
antifolate drugs occurred in P. falciparum due to mutations in dhfr and dhps, leading 
to altered structure and decreased drug affinity of dihyrofolate reductase (DHPS) and 






















   
 
Figure 2.6:     The chemical structure of the antimalarial drugs  
The antimalarial drugs that have been used in the treatment of malaria infection are 





i) Pyrimethamine ii) Proguanil 
i) Quinine ii) Plasmoquine iii) Chloroquine 
v) Halofantrine iv) Mefloquine vi) Primaquine 




Atovaquone, an electron transport inhibitor collapses plasmodial cells through the 
inhibition of parasite respiration and the depolarisation of mitochondrial membrane 
potential that are important for several biochemical processes of the malaria parasite 
(Figure 2.6D) (Gomez et al., 2018). Antibiotics inhibit protein translation inside the 
apicoplast of P. falciparum (Figure 2.6C) (Pasaje et al., 2016). Due to the resistance 
problem of these drugs, new strategies have been introduced as alternatives (Edwin et 
al., 2019). 
 
2.6.2 Current antimalarial drugs 
 
In order to solve the drug resistance problem, the combination of 
antimalarial drugs has been used for the treatment of uncomplicated malaria (Ouji et 
al., 2018). ACTs prove invaluable in the fight against malaria as compared to other 
strategies of combination therapies. However, resistance to ACTs has been existed 
recently (Conrad et al., 2019). This encourages scientists to conduct researches on the 
field of herbal medicine to produce new effective antimalarial drugs (Shen et al., 2015). 
 
2.7 Medicinal plants as a source of antimalarial drug candidates 
 
Medicinal plants have been used since ancient times for the treatment of 
malaria (Leonti et al., 2017). For instance, many plant species have been used as 
antimalarial medicines in Tanzania (Nondo et al., 2015). Up until now, 80% of the 
world’s population still depends upon traditional medicines on the treatment of malaria 
and other diseases (Tuo et al., 2015; Thomford et al., 2018) due to their cultural 
preferences, effectiveness, inexpensiveness, safety and abundant availability (National 
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Health Portal (NHP), 2016). Recently, many plant species have been introduced as 
antimalarial medicinal plants such as Clerodendrum viscosum Vent, Duranta repens 
L, Lantana camara L, Nyctanthes arbor tristis L, Dracaena reflexa Lamk, 
Cinnamosma fragrans H, Andropogon schoenanthus/nardis L, Desmodium 
mauritianum D.C, Ficus megapoda Bak and Quercus infectoria (Zin et al., 2019; 
Noronha et al., 2020). 
 
2.8 Quercus infectoria 
 
Q. infectoria is a medicinal herb that belongs to the family Fagaceae (see 
Figure 2.7) (Karimi et al., 2015). This plant is found in several countries such as 
Turkey, Persia, Syria, Greece and Cyprus. The parts of Q. infectoria that have been 
used for medicinal uses are mainly stem, bark, root, leaf, seed and galls (Hamad et al., 
2017). In Malaysia, Q. infectoria galls are locally known as biji manjakani (Basri et 
al., 2012). The galls appear on the branches of oak trees as a result of assault by gall 
wasp (Cypnis gallae-tincotoriae) (Mohammadi et al., 2016). The wasps penetrate 
young branches of the tree and lay their eggs inside them (Shahid et al., 2019). The 
galls are green-yellow in colour, slightly odour, strongly pungent taste, globular in 
shape, tuberculated surface and have 0.8-2.5 cm in diameter (Figure 2.8) (Baharuddin 
et al., 2015). The galls have been shown to have many biological activities such as 








The phytochemical constituents in Q. infectoria gall extracts are 1,2,3,4,6-
pentakis-ogalloylß-D-glucose (3.36-8.11%), 1,2,3,6-tetrakis-O-galloyl-ß-Dglucose 
(4.36-6.86%), digallate (1.8-2.38%), gallic acid (1.61-2.62%) and gallotannin (1-O,2-
O,6-O-Digalloyl-β-D-glucose) (2.16-2.64%), respectively. Major constituents 
analysed resulting from polyphenolic derivatives primarily hydrolysable tannins, and 
gallic acid (Table 2.1) (Vaidya et al., 2013; Abdullah et al., 2017). Pyrogallol have 
also been found among the phytoconstituents of Q. infectoria (Tayel et al., 2018). 




Pyrogallol also known as 1,2,3-trihydroxybenzene or pyrogallic acid, an 
organic compound belongs to the phenol family that is naturally present in oak, 
hardwood plants and many fruits such as pomegranate peel and date palm (Figure 2.9) 
(Wang et al., 2015; Shahzad et al., 2015; El Sohaimy et al., 2015; Baharuddin et al., 
2015; Panzella et al., 2017). Pyrogallol was recognised for the first time from the 
natural extract of Abrus precatorius, Linn seeds (Selvaraj et al., 2018). Nowadays, 
pyrogallol is commercially produced via thermal decarboxylation of gallic acid under 
high pressure and temperature. However, this method is limited via the strict reaction 
conditions, inaccessible raw material and the relatively low product yield (Wang et al., 
2018). Pyrogallol possesses antimalarial, antifungal and antipsoriatic properties 












Figure 2.7:     Quercus infectoria (oak tree) 
The tree grows to 4 to 6 feet tall, crooked, with bright and smooth leaves, acorn narrow 
and long, downy and scaly. Modified from Yahya (2018). 
 
 
 
 
 
